Our pipeline
HM-001: Non-muscle invasive bladder cancer
A drug development program for non-muscle invasive bladder cancer using the anti-tumor effect of the MA-T® system.
An investigator-initiated clinical trial PI/IIa was started in July 2023.
HM-001: Carcinomatous peritonitis (peritoneal dissemination)
A drug development programme for carcinomatous peritonitis/peritoneal dissemination such as colon cancer, ovarian cancer, and pancreatic cancer using a similar mechanism. We have confirmed the efficacy using a pancreatic cancer model.
ALKBH3 inhibitor
We have confirmed comparable drug efficacy as gemcitabine by subcutaneous administration of ALKBH3 inhibitor to a pancreatic cancer patient derived xenograft (PDX).
- View PDF
- Click image to enlarge